Blood Cancer is not a death sentence: Types, treatment and life Blood cancer is no longer a death sentence. Drugs can help you live a relatively normal life for many years. In this video, Dr. Rahul Bhargava, Director, Haematology and BMT, Fortis, Gurgaon (FMRI) explains different types of blood cancers and how they can be […]
Read More
”; Heart disease is a disorder that affects the ability of the heart to function normally. The common types of heart disease are coronary heart disease, pulmonary heart disease, ischaemic heart disease, hereditary heart disease, inflammatory heart disease, hypertensive disease and valvular disease. The common symptoms of heart disease are heaviness or pressure on the […]
Read More ”; Aspiring entrepreneurs and small business owners are often misled or misguided on the topic of how to properly conduct market research that uncovers a profitable niche.The path most unsuspecting entrepreneurs take is by ending up at keyword tool or database to begin their search.As a keyword research expert and founder of one of the […]
Read More
Triple Discordances in Receptor Status During Breast Cancer Local Progression and Metastases … Adrian Martuszewski,1 Patrycja Paluszkiewicz,1 Mateusz Nowak,1 Krzysztof Szewczyk,2,3 Urszula Staszek-Szewczyk2,4 1Wroclaw Medical University, Wroclaw, Poland; 2Wroclaw Medical University, Department of Oncology, Division of Surgical Oncology, Wroclaw, Poland; 3Wroclaw Regional Comprehensive Cancer Center, 1st Department of Surgical Oncology, Wroclaw, Poland; 4Wroclaw Regional Comprehensive […]
Read More (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer [unable to retrieve full-text content] Purpose: Resistance to treatment with endocrine therapy in patients with HR+, HER2− advanced breast cancer (ABC) is common and dual inhibition …Published at Tue, 13 Oct 2020 03:05:18 +0000
Read More
Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China Updated : October 13, 2020 10:59 AM IST Alembic Pharma said Curon obtains the exclusive development and commercialisation rights of Tenalisib for Greater China across all oncology indications. Alembic Pharmaceuticals, through its wholly-owned subsidiary, holds 50 percent ownership in Rhizen. […]
Read More Next Generation Immune Checkpoint Inhibitors and Stimulators Market is estimated to be worth … Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions Roots Analysis is pleased to announce the publication of its recent study, […]
Read More